Aurobindo Pharma gets FTC nod for $250m Lannett deal

Stock in focus after US antitrust clearance

Shares of Aurobindo Pharma Ltd were in focus after the company said its wholly owned subsidiary, Aurobindo Pharma USA Inc., has received approval from the US Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. The transaction size has been reported at around $150 million. Aurobindo has described the deal as being on a cash-free, debt-free basis. The company also said the transaction is inclusive of normalized working capital. The regulatory update is a key milestone because it removes a major hurdle for closing the acquisition. The company has indicated it expects to complete the transaction before the end of June 2026, subject to customary closing procedures.

What Aurobindo told the exchanges

In a filing to Indian stock exchanges, Aurobindo said it obtained the necessary FTC approval for the acquisition of the Lannett business. The company also said it anticipates the transaction will close before the end of the month and that it will keep exchanges informed if there are future developments. Aurobindo has positioned the clearance as an important step toward completing the acquisition it announced last year. The buyer in the structure is Aurobindo Pharma USA Inc., which is wholly owned by Aurobindo Pharma Ltd. The target is Lannett Company LLC, and the seller entity named in disclosures is LANNETT SELLER HOLDCO, INC.

Timeline: agreement in July 2025, clearance in June 2026

Aurobindo Pharma USA Inc. entered into a definitive agreement in July 2025 to acquire a 100% membership interest in Lannett Company LLC from LANNETT SELLER HOLDCO. The approval from the FTC was disclosed as having been received on June 19, 2026. With this step complete, the company said the deal is expected to close before the end of June 2026. The company has repeatedly framed the closing date as being within the month, subject to remaining formalities. This places the transaction near completion roughly a year after the definitive agreement was announced.

FTC consent order and the divestment condition

Some reports said the FTC cleared the $150 million acquisition through a consent order with conditions attached. Under these conditions, Aurobindo must divest four generic drug products to Quagen Pharmaceuticals LLC, a New Jersey-based generics maker, to address anticompetitive concerns. The requirement to divest products is aimed at preserving market competition. The clearance, while conditional, is still treated as the last major regulatory hurdle referenced in market coverage. The divestment step is presented as a prerequisite before the transaction can officially close. Aurobindo has said it expects to complete the deal before month-end after finishing customary procedures.

Why the Lannett acquisition matters to Aurobindo USA

Aurobindo has said the acquisition will significantly expand Aurobindo USA’s product offering in the relevant segment. It also adds a US-based manufacturing facility to Aurobindo’s network. Market reports linked the deal to strengthening Aurobindo’s portfolio in complex generics and controlled substances. Coverage also said the acquisition provides a manufacturing base in Indiana and offers entry into the attention-deficit/hyperactivity disorder medication market. Some commentary framed the expanded US footprint as a “reshoring” advantage ahead of anticipated US pharmaceutical tariffs. Separately, the company said the transaction is expected to be immediately accretive to the Aurobindo Group’s earnings per share.

How the stock traded on the news

Aurobindo Pharma’s share price moved higher in early trade following the regulatory update. One market update said the stock gained 2% to ₹1,472 in an otherwise negative market. Another said that at 11:30 AM, it traded 1.7% higher at ₹1,467, with trades of around 1 lakh equity shares on the BSE versus a two-week average volume of around 34,000 shares. On June 19, 2026, the stock was also reported at ₹1,461.40, up ₹17.70 or 1.23%, after touching a day high around ₹1,470. Another data point for the same session said the stock opened at ₹1,454, hit a day low of ₹1,446.40, and traded near ₹1,461.40. The stock was also described as having gained 5.5% over the last three trading sessions at the time of reporting.

Performance versus sector and longer-term context

Aurobindo Pharma shares were reported to be up 26% in 2026 so far, compared with an 8% rise in the Nifty Pharma index during the same period. Another update said the stock had gained 22.97% year to date and 35.52% over the past year. The FTC clearance also arrived close to a separate development flagged by the market: Eugia Pharma Specialities’ Unit III facility in Telangana was classified as “Official Action Indicated” on June 12. In that context, the US regulatory clearance on the acquisition gave investors a fresh, positive catalyst to track. Attention now shifts to completion steps and the initial phase of integration once the transaction closes.

Key facts at a glance

Market impact and what investors are watching

The immediate market impact was a positive share-price reaction, reflecting relief that a key regulatory step has been completed. The conditional nature of the clearance matters because it adds an execution task before closing, namely the divestment of four generic products to Quagen Pharmaceuticals. Investors are also watching whether the company meets its stated goal of closing before the end of June 2026. In parallel, market participants continue to track US regulatory developments across Aurobindo’s broader network, including updates related to the Eugia facility classification reported earlier in June. For Aurobindo, the strategic emphasis in coverage has been on expanding its US portfolio and adding US manufacturing capacity through Lannett’s facility.

Conclusion

Aurobindo Pharma has secured FTC approval for its proposed $150 million acquisition of Lannett Company LLC, clearing a major hurdle for a deal announced in July 2025. With conditions including the divestment of four generic products to Quagen Pharmaceuticals, the company has said it expects to complete the acquisition before the end of June 2026. The next updates investors are likely to watch are the completion of closing formalities and confirmation that the transaction has officially closed, along with any integration milestones disclosed after completion.